Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma

被引：2

作者：

Mitchell, Dana ^{[1
]}

Dey, Mahua ^{[1
]}

机构：

[1] Indiana Univ Sch Med, Dept Neurosurg, IU Simon Canc Ctr, Indianapolis, IN 46202 USA

来源：

TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷

关键词：

D O I：

10.21037/tcr.2019.05.24

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S577 / S579

页数：3

共 6 条

[1] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].

Cloughesy, Timothy F. ;

Mochizuki, Aaron Y. ;

Orpilla, Joey R. ;

Hugo, Willy ;

Lee, Alexander H. ;

Davidson, Tom B. ;

Wang, Anthony C. ;

Ellingson, Benjamin M. ;

Rytlewski, Julie A. ;

Sanders, Catherine M. ;

Kawaguchi, Eric S. ;

Du, Lin ;

Li, Gang ;

Yong, William H. ;

Gaffey, Sarah C. ;

Cohen, Adam L. ;

Mellinghoff, Ingo K. ;

Lee, Eudocia Q. ;

Reardon, David A. ;

O'Brien, Barbara J. ;

Butowski, Nicholas A. ;

Nghiemphu, Phioanh L. ;

Clarke, Jennifer L. ;

Arrillaga-Romany, Isabel C. ;

Colman, Howard ;

Kaley, Thomas J. ;

De Groot, John F. ;

Liau, Linda M. ;

Wen, Patrick Y. ;

Prins, Robert M. .

NATURE MEDICINE, 2019, 25 (03) :477-+

[2] Recurrent glioma clinical trial, CheckMate-143: the game is not over yet [J].

Filley, Anna C. ;

Henriquez, Mario ;

Dey, Mahua .

ONCOTARGET, 2017, 8 (53) :91779-91794

[3] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[4] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Rini, Brian I. ;

Plimack, Elizabeth R. ;

Stus, Viktor ;

Gafanov, Rustem ;

Hawkins, Robert ;

Nosov, Dmitry ;

Pouliot, Frederic ;

Alekseev, Boris ;

Soulieres, Denis ;

Melichar, Bohuslav ;

Vynnychenko, Ihor ;

Kryzhanivska, Anna ;

Bondarenko, Igor ;

Azevedo, Sergio J. ;

Borchiellini, Delphine ;

Szczylik, Cezary ;

Markus, Maurice ;

McDermott, Raymond S. ;

Bedke, Jens ;

Tartas, Sophie ;

Chang, Yen-Hwa ;

Tamada, Satoshi ;

Shou, Qiong ;

Perini, Rodolfo F. ;

Chen, Mei ;

Atkins, Michael B. ;

Powles, Thomas .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1116-1127

[5] Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) [J].

Schachter, Jacob ;

Ribas, Antoni ;

Long, Georgina V. ;

Arance, Ana ;

Grob, Jean-Jacques ;

Mortier, Laurent ;

Daud, Adil ;

Carlino, Matteo S. ;

McNeil, Catriona ;

Lotem, Michal ;

Larkin, James ;

Lorigan, Paul ;

Neyns, Bart ;

Blank, Christian ;

Petrella, Teresa M. ;

Hamid, Omid ;

Zhou, Honghong ;

Ebbinghaus, Scot ;

Ibrahim, Nageatte ;

Robert, Caroline .

LANCET, 2017, 390 (10105) :1853-1862

[6] Regulation and Function of the PD-L1 Checkpoint [J].

Sun, Chong ;

Mezzadra, Riccardo ;

Schumacher, Ton N. .

IMMUNITY, 2018, 48 (03) :434-452

← 1 →